Join us for a discussion of the Eco-friendly process to improve oral bioavailability of poorly soluble API
Session Abstract
Many factors limit the effectiveness of oral treatments, including the poor bioavailability of some Active Pharmaceutical Ingredients (API). Considering these issues, particle size reduction and nanoencapsulation of BCS class II or IV API have become innovative strategies to improve drug solubility but also to control its release and avoid hepatic first-pass effects. In this session, we will present how Microfluidizer® technology (high-pressure homogenization) through a solvent-free manufacturing process can help solve bioavailability issues and is particularly suitable for industrial transposition.
Topics include:
- Microfluidizer® technology – from best-in-class results to scalability
- Bioavailability challenges
- Particle size reduction
- Lipid-based Nanoparticles Development
- Poorly-soluble API nanoencapsulation
- Industrial manufacturing
Presenters:
Innovation leader
Vanessa BOURGEAUX brings 15 years of experience in R&D and pharmaceutical development. She initiated her career at erytech pharma, a biotech company where she held the position of global project leader for a drug product candidate and actively contributed to the development of erythrocytes as drug carriers for oncology and sickle cell disease.
In 2020, Vanessa joined Skyepharma, a CDMO specialized in solid oral dosage forms. As project manager in New Product Introduction department, her mission is oriented towards Innovation and collaborative partnerships.Vanessa graduated in organic chemistry and holds a PhD in biochemistry and cellular aspects of biology. She is the inventor of 12 patents and authors of numerous scientific publications.
Ph.D Student
Oksana obtained a double degree in pharmacy and a master 2 in industrial cosmetology with a specialization in formulation at the University of Lyon (France).
Following her studies, she taught galenics for a year at university to pharmacy students. Wishing to develop her expertise in formulation, she is currently a PhD student at LAGEPP (Lyon, France), in partnership with Skyepharma, and works on the development of lipid-based nanoparticles, from proof of concept to manufacturing process optimization.
Applications Engineer
As an Applications Engineer, Chris has worked with a wide variety of materials, including nanoemulsions, cell disruption and lipid nanoparticles, while performing proof of concept, process optimization, and scale-up tests at Microfluidics’ facility located in Westwood, MA.
During this time, Chris has amassed knowledge of both Microfluidizer® Processor Technology and the various applications which utilize the technology. Prior to working for Microfluidics, Chris earned a B.S. in Chemical Engineering from Syracuse University.
